Form 4: Kronos Bio Director Disposes of Shares and Options Following Concentra Biosciences Merger Completion

A director of Kronos Bio, Inc. has reported the disposition of common stock and the cancellation of stock options as a result of the company's acquisition by Concentra Biosciences, LLC for $0.57 per share cash plus a contingent value right.

Summary

• Taiyin Yang, a Director of Kronos Bio, Inc. (KRON), reported the disposition of 11,333 shares of common stock at a price of $0.57 per share.
• The disposition occurred on June 20, 2025, as a direct result of the merger between Kronos Bio, Inc. and Concentra Biosciences, LLC.
• The merger, pursuant to an Agreement and Plan of Merger dated May 1, 2025, involved a tender offer completed on June 18, 2025.
• Shareholders received $0.57 in cash per share (the "Cash Amount") and one non-transferable contractual contingent value right (CVR) for each share.
• Following the tender offer, Concentra Merger Sub IV, Inc. merged with Kronos Bio, Inc., making Kronos Bio a wholly-owned subsidiary of Concentra Biosciences, LLC.
• All outstanding options to purchase Kronos Bio shares became fully vested and exercisable immediately prior to the merger's effective time.
• Unexercised options were cancelled and converted into a cash amount equal to the product of (1) the excess of the Cash Amount ($0.57) over the option's exercise price and (2) the number of shares underlying the option, plus one CVR per underlying share.
• Options with an exercise price equal to or greater than the Cash Amount ($0.57) were cancelled for no consideration.
• Taiyin Yang's stock options, with exercise prices ranging from $0.95 to $28.58, were cancelled, with those above $0.57 receiving no consideration.

Sentiment

Score: 3

Explanation: The sentiment is largely negative for former public shareholders and the reporting person's option holdings, given the very low cash acquisition price and the cancellation of a large number of stock options for no consideration. While the merger provides a definitive exit, the terms suggest significant value destruction for prior investors. The CVR offers speculative future upside but is not guaranteed.

Positives

• The completion of the merger provides a definitive outcome for Kronos Bio shareholders, offering a cash component and potential future value through CVRs.
• The director received cash for their common stock holdings, providing liquidity.

Negatives

• A significant number of the director's stock options (131,350 options with exercise prices ranging from $0.95 to $28.58) were cancelled for no consideration, indicating that the merger price was substantially below the value at which these options were granted.
• The cash component of $0.57 per share is a very low valuation, suggesting significant value erosion for prior shareholders.
• The non-transferable nature of the CVRs limits liquidity and immediate value realization for shareholders.

Risks

• The value of the Contingent Value Rights (CVRs) is uncertain and dependent on future events or performance milestones, which may or may not be achieved.
• Shareholders who acquired Kronos Bio shares at prices significantly higher than the $0.57 cash offer will incur substantial losses.
• The company is no longer a publicly traded entity, removing transparency and direct shareholder influence.

Future Outlook

Kronos Bio, Inc. has become a wholly-owned subsidiary of Concentra Biosciences, LLC, ceasing to be an independent publicly traded company. The future financial outcome for former shareholders holding CVRs will depend entirely on the terms and achievement of milestones outlined in the Contingent Value Rights Agreement.

Industry Context

This Form 4 filing signifies the completion of an acquisition in the biotechnology sector, a common occurrence where smaller companies, particularly those facing clinical or financial challenges, are acquired by larger entities. The low cash price per share and the cancellation of high-strike options suggest that Kronos Bio may have faced significant hurdles prior to the acquisition, a scenario not uncommon in the high-risk, high-reward biotech industry.

Comparison to Industry Standards

• The acquisition via a tender offer followed by a merger is a standard M&A mechanism in the U.S. market.
• The inclusion of a Contingent Value Right (CVR) is a common feature in biotech acquisitions, particularly when there is uncertainty regarding the future value of pipeline assets or clinical outcomes, allowing the buyer to cap upfront costs while offering potential upside to sellers.
• The significant disparity between the acquisition price ($0.57 cash) and the exercise prices of many outstanding stock options (up to $28.58) indicates a substantial decline in the company's market valuation prior to the acquisition, which is a frequent outcome for biotech companies whose drug development programs do not meet expectations or face setbacks.

Stakeholder Impact

• Shareholders: Received $0.57 cash per share and one CVR, indicating a low valuation for their equity.
• Employees/Management: The change in ownership may lead to changes in corporate structure, roles, and compensation, though specific details are not in this filing.
• Creditors: The merger likely impacts the company's financial structure and debt obligations, now under the parent company's purview.

Next Steps

• The terms of the Contingent Value Rights Agreement will dictate any potential future payments to former shareholders.
• Kronos Bio, Inc. will operate as a wholly-owned subsidiary of Concentra Biosciences, LLC.

Key Dates

Keywords

SEC Form 4, Kronos Bio, Concentra Biosciences, Merger, Tender Offer, Stock Disposition, Director, Taiyin Yang, Contingent Value Right, KRON, Acquisition